178 related articles for article (PubMed ID: 37961677)
1. Effect of statins and testosterone replacement therapy on incident cardiovascular disease among male hormone-related cancer survivors.
El Haddad D; Kim H; Polychronopolou E; Baillargeon J; Villasante-Tezanos A; Kuo YF; Gilani S; Khalife WI; Lopez DS
Res Sq; 2023 Nov; ():. PubMed ID: 37961677
[TBL] [Abstract][Full Text] [Related]
2. Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015.
Lopez DS; Kim H; Polychronopoulou E; Taha S; Tsilidis KK; Villasante-Tezanos A; Peek MK; Gilani S; Khera M; Baillargeon J; Kuo YF; Canfield S
Cancer Epidemiol; 2022 Aug; 79():102172. PubMed ID: 35523034
[TBL] [Abstract][Full Text] [Related]
3. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.
Lopez DS; Polychronopoulou E; Tsilidis KK; Khera M; Su LJ; Fowke JH; Peek MK; Kuo YF; Markides K; Canfield S
Cancer Prev Res (Phila); 2021 Jul; 14(7):719-728. PubMed ID: 33879532
[TBL] [Abstract][Full Text] [Related]
4. The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
Lopez DS; Huang D; Tsilidis KK; Canfield S; Khera M; Baillargeon JG; Kuo YF; Peek MK; Platz EA; Markides K
Cancer Causes Control; 2021 Sep; 32(9):965-976. PubMed ID: 34041642
[TBL] [Abstract][Full Text] [Related]
5. Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Lopez DS; Malagaris I; Polychronopoulou E; Tsilidis KK; Milani SA; Kristen Peek M; Villasante-Tezanos A; Alzweri L; Baillargeon J; Kuo YF; Canfield S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):792-803. PubMed ID: 35902376
[TBL] [Abstract][Full Text] [Related]
6. Use of weight loss medications in relation with prostate, colorectal and male breast cancers among older men: SEER-Medicare 2007-2015.
Lopez DS; Kim H; Polychronopoulou E; Torres-Sanchez LE; Villasante-Tezanos A; Baillargeon J; Canfield S; Kuo YF
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8255-8265. PubMed ID: 37067547
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Replacement Therapy in Relation With Cardiovascular Disease in Cisgender Women and Transgender People.
Lopez DS; Mulla JS; El Haddad D; Tahashilder MI; Polychronopolou E; Baillargeon J; Kuo YF; Gilani S; Khalife WI
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1515-e1523. PubMed ID: 37392459
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the impact of pre-diagnostic use of statins and testosterone replacement therapy on mortality outcomes in older men with hormone-related cancers: Surveillance, Epidemiology, and End Results-Medicare 2007-2015.
Hussain MR; Abdelgadir O; Polychronopoulou E; Tsilidis KK; Alzweri L; Villasante-Tezanos A; Baillargeon J; Canfield S; Kuo YF; Lopez DS
Andrology; 2024 Feb; ():. PubMed ID: 38421134
[TBL] [Abstract][Full Text] [Related]
9. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Chen T; Li S; Eisenberg ML
J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
[TBL] [Abstract][Full Text] [Related]
11. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.
Lopez DS; Huang D; Tsilidis KK; Khera M; Williams SB; Urban RJ; Panagiotou OA; Kuo YF; Baillargeon J; Farias A; Krause T
Clin Endocrinol (Oxf); 2019 Dec; 91(6):885-891. PubMed ID: 31498469
[TBL] [Abstract][Full Text] [Related]
12. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
Khera M; Miner M; Jaffe J; Pastuszak AW
J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
[TBL] [Abstract][Full Text] [Related]
13. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use and incident cardiovascular events among older breast cancer survivors.
Gegechkori N; Egorova N; Mhango G; Wisnivesky JP; Lin JJ
Breast; 2019 Oct; 47():28-32. PubMed ID: 31310951
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
16. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors.
Schoormans D; van de Poll-Franse L; Vissers P; van Herk-Sukel MPP; Pedersen SS; Rottmann N; Horsbøl T; Dalton S; Denollet J
Breast Cancer Res Treat; 2017 Nov; 166(1):259-266. PubMed ID: 28717854
[TBL] [Abstract][Full Text] [Related]
18. To T or not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatus among Men who Have Sex with Men.
Haberlen SA; Jacobson LP; Palella FJ; Dobs A; Plankey M; Lake JE; Kingsley LA; Stall R; Post WS; Brown TT
HIV Med; 2018 Oct; 19(9):634-644. PubMed ID: 29989322
[TBL] [Abstract][Full Text] [Related]
19. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
Rhoden EL; Morgentaler A
J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
